Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer

  • Technology appraisal guidance
  • TA740
  • Published: 

Tools and resources

Tools and resources to help you put the guidance into practice.

Resource impact

Guidance into practice